Taiwan · Delayed Price · Currency is TWD Taiyen Biotech Statistics
Total Valuation
Taiyen Biotech has a market cap or net worth of TWD 6.31 billion. The enterprise value is 4.61 billion.
| Market Cap | 6.31B |
| Enterprise Value | 4.61B |
Important Dates
The next estimated earnings date is Monday, August 3, 2026.
| Earnings Date | Aug 3, 2026 |
| Ex-Dividend Date | Aug 20, 2025 |
Share Statistics
Taiyen Biotech has 200.00 million shares outstanding. The number of shares has increased by 0.54% in one year.
| Current Share Class | 200.00M |
| Shares Outstanding | 200.00M |
| Shares Change (YoY) | +0.54% |
| Shares Change (QoQ) | -0.22% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 6.04% |
| Float | 99.69M |
Valuation Ratios
The trailing PE ratio is 16.02.
| PE Ratio | 16.02 |
| Forward PE | n/a |
| PS Ratio | 1.92 |
| PB Ratio | 0.91 |
| P/TBV Ratio | 0.92 |
| P/FCF Ratio | 19.05 |
| P/OCF Ratio | 9.86 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.22, with an EV/FCF ratio of 13.93.
| EV / Earnings | 11.62 |
| EV / Sales | 1.41 |
| EV / EBITDA | 6.22 |
| EV / EBIT | 9.40 |
| EV / FCF | 13.93 |
Financial Position
The company has a current ratio of 3.25, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.25 |
| Quick Ratio | 2.61 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.16 |
| Debt / FCF | 0.36 |
| Interest Coverage | 165.29 |
Financial Efficiency
Return on equity (ROE) is 5.84% and return on invested capital (ROIC) is 7.60%.
| Return on Equity (ROE) | 5.84% |
| Return on Assets (ROA) | 3.69% |
| Return on Invested Capital (ROIC) | 7.60% |
| Return on Capital Employed (ROCE) | 6.61% |
| Weighted Average Cost of Capital (WACC) | 4.99% |
| Revenue Per Employee | 7.28M |
| Profits Per Employee | 882,316 |
| Employee Count | 487 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 5.00 |
Taxes
In the past 12 months, Taiyen Biotech has paid 96.53 million in taxes.
| Income Tax | 96.53M |
| Effective Tax Rate | 19.47% |
Stock Price Statistics
The stock price has decreased by -3.37% in the last 52 weeks. The beta is 0.14, so Taiyen Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.14 |
| 52-Week Price Change | -3.37% |
| 50-Day Moving Average | 31.71 |
| 200-Day Moving Average | 31.88 |
| Relative Strength Index (RSI) | 47.81 |
| Average Volume (20 Days) | 129,254 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Taiyen Biotech had revenue of TWD 3.28 billion and earned 397.04 million in profits. Earnings per share was 1.97.
| Revenue | 3.28B |
| Gross Profit | 1.34B |
| Operating Income | 490.91M |
| Pretax Income | 495.84M |
| Net Income | 397.04M |
| EBITDA | 732.25M |
| EBIT | 490.91M |
| Earnings Per Share (EPS) | 1.97 |
Balance Sheet
The company has 1.81 billion in cash and 118.94 million in debt, with a net cash position of 1.70 billion or 8.48 per share.
| Cash & Cash Equivalents | 1.81B |
| Total Debt | 118.94M |
| Net Cash | 1.70B |
| Net Cash Per Share | 8.48 |
| Equity (Book Value) | 6.91B |
| Book Value Per Share | 34.38 |
| Working Capital | 1.95B |
Cash Flow
In the last 12 months, operating cash flow was 640.13 million and capital expenditures -308.98 million, giving a free cash flow of 331.15 million.
| Operating Cash Flow | 640.13M |
| Capital Expenditures | -308.98M |
| Depreciation & Amortization | 241.34M |
| Net Borrowing | -29.93M |
| Free Cash Flow | 331.15M |
| FCF Per Share | 1.66 |
Margins
Gross margin is 40.77%, with operating and profit margins of 14.98% and 12.11%.
| Gross Margin | 40.77% |
| Operating Margin | 14.98% |
| Pretax Margin | 15.13% |
| Profit Margin | 12.11% |
| EBITDA Margin | 22.34% |
| EBIT Margin | 14.98% |
| FCF Margin | 10.10% |
Dividends & Yields
This stock pays an annual dividend of 1.40, which amounts to a dividend yield of 4.44%.
| Dividend Per Share | 1.40 |
| Dividend Yield | 4.44% |
| Dividend Growth (YoY) | 8.33% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 65.48% |
| Buyback Yield | -0.54% |
| Shareholder Yield | 3.91% |
| Earnings Yield | 6.29% |
| FCF Yield | 5.25% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 16, 2013. It was a reverse split with a ratio of 0.719181284.
| Last Split Date | Dec 16, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.719181284 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |